Jun. 13 at 4:44 PM
Commercial-stage oncology focused biopharma share price changes Q2 2026 to date (sorted gain to loss)
$CORT has recovered & then some after its Relacorilant was first rejected for Cushing's Disease just before the onset of 2026 then approved for certain ovarian cancers on March 25, 2026.
$LEGN has recovered from the beating it took after a BP published better results in MM last December.
This is not investment advice & we are not clinicians but some believe the
$IOVA risk reward profile is massively misunderstood.
$VSTM AF/FAK combo is more or less (perhaps slightly less) to CTIC's Vonjo. Vonjo was acquired for
$1.7B. Also, there are near term updated data reads for VSTM's VS-7375 candidate. We track job openings at VSTM & noted certain revenue related positions in accounting & commercial ops were taken down before the new CCO started. It may be nothing as the positions c/h/b filled for all we know.
Is the JAZZ miss good for a
$ZYME exit? Anyone?
Hey we're only sharing observations.
